Those participants who did not start an SGLT2 inhibitor during post-trial follow-up were more likely to be from Asia, less likely to have prior diabetes, had lower eGFR, notably higher kidney failure risk, and were less likely to be on a RAS inhibitor (Table S3). The gene discussed is SLC5A2; the disease is diabetes mellitus.